MaxCyte, Inc. announced today a strategic collaboration with leading academic research institution, Washington University in St. Louis (“Washington University”) to advance next-generation Chimeric Antigen Receptor (CAR)-based cell therapies for acute myeloid leukemia (AML).
MaxCyte and Washington University will develop unique immunotherapy drug candidates, based on MaxCyte’s proprietary cell engineering platform technology, CARMA.
This collaboration builds on MaxCyte’s efforts with The Johns Hopkins Kimmel Cancer Center around pre-clinical development of CAR therapy for solid cancers.
{iframe}http://www.maxcyte.com/company/PressReleases/2016/WashU%20Maxcyte%20Press%20Release%2020DEC16%20FINAL%20US%20VERSION.pdf{/iframe}